Item 8.01 Other Events. On January 13, 2021, Inhibrx, Inc. (the "Company") issued a press release announcing the U.S. Food and Drug Administration has granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. INBRX-109 is a precisely engineered tetravalent single domain antibody-based therapeutic candidate that agonizes death receptor 5 (DR5) to induce tumor selective programmed cell death.



The full text of the Company's press release regarding this announcement is
filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein
by reference.
Item 9.01.  Financial Statements and Exhibits.
(d) Exhibits.
 Exhibit No.      Description
99.1                Press Release issued by Inhibrx, Inc. on January 13, 2021

© Edgar Online, source Glimpses